Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis

Dr Kremyanskaya discusses the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib and recently approved JAK inhibitors, and next steps for the investigation of BET inhibitors in this population.

Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Marina Kremyanskaya, MD, PhD, to discuss the results from the phase 1/2 MANIFEST trial (NCT02158858) with pelabresib (CPI-0610) plus ruxolitinib (Jakafi) in patients with myelofibrosis. Kremyanskaya is the medical director for the inpatient oncology unit at The Mount Sinai Hospital, and an assistant professor of medicine, hematology, and medical oncology at the Icahn School of Medicine at Mount Sinai in New York, New York.

Pelabresib is an investigational, selective oral bromodomain and extraterminal domain (BET) inhibitor under evaluation in the global, open-label, nonrandomized, multicohort MANIFEST trial. The trial was divided into 4 cohorts to evaluate pelabresib in patients with JAK inhibitor–pretreated myelofibrosis (cohort 1); pelabresib plus ruxolitinib in patients with ruxolitinib-pretreated myelofibrosis (cohort 2); pelabresib plus ruxolitinib in patients with JAK inhibitor–naïve myelofibrosis (cohort 3); and pelabresib alone in patients with essential thrombocythemia (cohort 4).

In our exclusive interview, Dr Kremyanskaya discussed the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib and recently approved JAK inhibitors, and next steps for the investigation of BET inhibitors in this population.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.